Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Sponsor: Stemline Therapeutics, Inc.
A PHASE1/PHASE2 clinical study on Chronic Myelomonocytic Leukemia and Myelofibrosis, this trial is completed. The trial is conducted by Stemline Therapeutics, Inc. and has accumulated 16 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1/PHASE2
Phase: PHASE2 → PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 11 earlier versions
-
May 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Apr 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stemline Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .